AMB-CHMINACA

AMB-CHMINACA or MMB-CHMINACA (also known as MA-CHMINACA) is an indazole-based synthetic cannabinoid[1] that is a potent agonist of the CB1 receptor and has been sold online as a designer drug.[2][3][4]

AMB-CHMINACA
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC21H29N3O3
Molar mass371.481 g·mol−1
3D model (JSmol)

AMB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[5]

Sweden's public health agency classified AMB-CHMINACA as a narcotic substance, on January 18, 2019.[6]

See also

References

  1. Akamatsu S, Yoshida M (January 2016). "Fragmentation of synthetic cannabinoids with an isopropyl group or a tert-butyl group ionized by electron impact and electrospray". Journal of Mass Spectrometry. 51 (1): 28–32. Bibcode:2016JMSp...51...28A. doi:10.1002/jms.3722. PMID 26757069.
  2. "MA-CHMINACA". Cayman Chemical. Retrieved 21 July 2015.
  3. "MA-CHMINACA". Southern Association of Forensic Scientists. Archived from the original on 27 September 2015. Retrieved 21 July 2015.
  4. Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
  5. "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived from the original on 15 July 2015. Retrieved 21 July 2015.
  6. "Sexton nya ämnen klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 18 January 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.